
Vimian Group AB (publ)
VIMGF
Updated: 24/09/2026, 01:15:00
Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary applications for both livestock and companion animal health markets. Moreover, its VetFamily brand operates a membership-based platform that provides veterinary clinics with procurement services, tech-enabled operations including online marketing, education, and HR support, as well as a professional community. The company also supplies orthopedic implants to veterinarians and universities through its Movora brand. Established in 2020, Vimian Group is based in Stockholm, Sweden.
No summaries found.
- Share price
- $2.77
- Market cap
- $1.46B
- Exchange
- OTC
- Currency
- USD
- CEO
- Alireza Tajbakhsh
- Employees
- 1,300
- IPO date
- 22/08/2022
- Beta
- 1.191
- Last dividend
- $0.00
- Day range
- $2.68 – $2.77
- 52-week range
- $2.68 – $3.01
- 1-day performance
- 0.00%
- 1-year performance
- 3.36%
- Current drawdown (1Y)
- -7.97%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- SE0015961982
- Created
- 07/12/2025, 14:58:36
- Last update
- 24/09/2026, 01:15:00
Track Vimian Group AB (publ) with an AI analyst
See which prediction-market events move VIMGF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.